Skip to main content
    R

    Repligen Corporation (RGEN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $162.18
    -0.60 (-0.37%)

    Market Cap: $10.41B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Repligen Corporation (RGEN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Repligen (RGEN) has a market cap of $10.41B and an enterprise value of $10.24B. Its return on invested capital of 0.10% compares with a 7.13% median across 9 similar companies.

    Total Valuation

    Enterprise value is 1.63% below the market cap, as cash exceeds debt.

    Market Cap$10.41B
    Enterprise Value$10.24B
    Latest price (Nov 17, 2026)$162.18

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateOct 27, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.25% in the quarter ended Sep 30, 2026 and grew 3077.65% a year over 2 years.

    Shares Outstanding56.56M
    Shares Change (YoY)+0.52%
    Shares Change (QoQ)+0.25%
    Share Count Growth (2Y CAGR)+3077.65%

    Valuation Ratios

    Sales and book value multiples are 11.4x and 4.4x. Its year-end P/E ranged from 51.6x to 138.6x from 2016 to 2025.

    P/E Ratio79.5x
    Forward P/E76.7x
    P/S Ratio11.4x
    Forward P/S12.3x
    P/B Ratio4.4x
    P/TBV Ratio13.4x
    P/FCF Ratio86.0x
    P/OCF Ratio80.1x
    PEG Ratio3.2

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 90.7x EBITDA and 84.4x free cash flow.

    EV / Sales12.7x
    EV / EBITDA90.7x
    EV / FCF84.4x

    Price Statistics

    The stock is up 6.44% over 52 weeks and trades 8.33% below its 50-day average.

    Beta (1Y)1.21
    52-Week Change+6.44%
    1-Month Change-8.08%
    3-Month Change-8.04%
    6-Month Change+49.45%
    5-Year Change-39.09%
    10-Year Change+519.32%
    Total Return (1Y)+6.44%
    Total Return (3Y CAGR)+2.50%
    Total Return (5Y CAGR)-10.35%
    Return vs SPY (1Y)-5.60%
    Max Drawdown (1Y)-40.28%
    Max Drawdown (3Y)-50.64%
    Sharpe Ratio (1Y)0.13
    Correlation with SPY (1Y)0.36
    50-Day Average$176.92
    200-Day Average$145.39
    52-Week Range$100.99 to $198.87
    RSI (14 Days)39.6
    Average Volume (20 Days)1.24M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 9.88x current liabilities, and total debt is 0.27x shareholder equity.

    Current Ratio9.88x
    Quick Ratio8.43x
    Debt / Equity0.27x
    Debt / EBITDA5.62x
    Debt / FCF5.23x
    Interest Coverage0.18x

    Returns and Efficiency

    Return on invested capital is 0.10% over the last 12 months, against a 5-year average of 2.37%.

    Return on Equity (ROE)-0.56%
    Return on Assets (ROA)-0.40%
    Return on Invested Capital (ROIC)0.10%
    ROE (5Y Average)3.98%
    ROA (5Y Average)2.96%
    ROIC (5Y Average)2.37%
    Asset Turnover0.28x
    Inventory Turnover2.02x
    Receivables Turnover5.22x
    Cash Conversion Cycle221 days

    Scores

    RGEN has an Altman Z-Score of 7.54, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score7.54
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $805.61M over the last 12 months is up 13.80% from the 12 months before.

    Revenue$805.61M
    Revenue Growth (YoY)+13.80%
    Gross Profit$433.14M
    Operating Income$18.24M
    Pretax Income$8.23M
    Net Income-$11.80M
    EBITDA$99.27M
    Reported EPS (TTM)$2.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 71.33% of the $2.93B in total assets.

    Cash and Equivalents$726.96M
    Total Debt$557.85M
    Net Cash$169.11M
    Net Cash Per Share$2.99
    Working Capital$1.12B
    Shareholder Equity$2.09B
    Book Value Per Share$36.98
    Tangible Book Value$686.13M
    Tangible Book Per Share$12.13
    Total Assets$2.93B
    Total Liabilities$834.67M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $23.14M of capital spending, operating cash flow left $106.72M of free cash flow.

    Operating Cash Flow$129.86M
    Capital Expenditures$23.14M
    Free Cash Flow$106.72M
    FCF Per Share$1.68
    Depreciation and Amortization$115.82M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 2.26%, against a 5-year average of 12.49%.

    Gross Margin53.77%
    Operating Margin2.26%
    Pretax Margin1.02%
    Net Margin-1.47%
    EBITDA Margin12.32%
    FCF Margin13.25%
    Gross Margin (5Y Average)50.97%
    Operating Margin (5Y Average)12.49%
    Net Margin (5Y Average)10.11%

    Growth

    Revenue fell 2.70% a year over 3 years, and EPS 19.52% a year.

    Revenue Growth (3Y CAGR)-2.70%
    Revenue Growth (5Y CAGR)+15.05%
    EPS Growth (3Y CAGR)-19.52%
    EPS Growth (5Y CAGR)+0.60%
    FCF Growth (3Y CAGR)+2.48%
    FCF Growth (5Y CAGR)+18.51%
    Operating Income Growth (3Y CAGR)-37.38%
    Book Value Per Share Growth (2Y CAGR)+2.88%
    Tangible Book Per Share Growth (2Y CAGR)+2.36%

    Revenue and profit by year

    Dividends and Yields

    RGEN does not pay a dividend. Its free cash flow yield is 1.16%.

    Earnings Yield1.26%
    FCF Yield1.16%
    Shareholder Yield0.00%

    Peer Position

    Against 11 similar companies, RGEN has the 2nd highest P/E and the 2nd highest P/S.

    P/E Ratio79.5x vs 20.7x median
    P/S Ratio11.4x vs 2.9x median
    ROIC0.10% vs 7.13% median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.80% vs +7.59% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 20.37% and EPS growth at 24.54% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+20.37%
    EPS Growth Forecast (2Y CAGR)+24.54%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RGEN

    What is RGEN's market cap?

    Repligen has a market cap of $10.41B. Its enterprise value, which adds debt and subtracts cash, is $10.24B.

    What is RGEN's P/E ratio?

    Repligen has a trailing P/E ratio of 79.5x and a forward P/E of 76.7x.

    How many shares of RGEN are outstanding?

    Repligen has 56.56M shares outstanding. The count is up 0.52% from a year earlier.

    Does RGEN pay a dividend?

    No. Repligen does not pay a dividend.

    How much debt does RGEN have?

    Repligen has $557.85M of total debt and $726.96M of cash and equivalents, a net cash position of $169.11M.